The insider-buying table is unchanged for a third straight cycle — TSLA (+$219.9M), CRSP (+$28.1M), ASAN (+$8.7M), INTC (+$2.4M), and TSM (+$1.6M) — with no fresh Form-4 filing activity behind any of them. For a fourth straight cycle, no name in this 59-stock universe closes below RSI 30 on the summary basis — the closest reading this cycle is EOSE at RSI 38.5 (a structurally broken small-cap energy-storage name, -54.14% on the year), not a returning name from prior cycles. BE's multi-cycle reversal, which cooled sharply last cycle, resumed this cycle — its cushion above the 200-day widened back to +11.8% from +8.0%, and its 30-day print flipped back positive to +28.71% from -7.68%, though its one-year return cooled to +284.62% from +349.36% as the trailing window rolled forward. MRNA cooled on the short window (RSI 71.6 → 63.5, 7D -4.89%) but kept climbing on the 30-day and one-year windows — 30-day now +153.24% (was +149.92%), one-year +463.91% (was +453.51%) — this desk checked news (fetched 2026-08-25, ok, not stale) and research/stock-events/ for MRNA; no driver was found for either this week's pullback or the underlying multi-week climb, for a second straight cycle. ARM's reversal stabilized — 30-day flipped back positive to +6.3% from -14.14%, though its one-year return cooled to +67.7% from +82.56% and its 200-day cushion narrowed to +19.9% from +23.4%. ISRG's divergence between chart and thesis flag persisted and worsened — regime still collapse, vs-SMA200 now -20.5% (was -19.9%), one-year -21.37% (was -19.38%), while thesisState still reads intact. NVDA and MRVL both reported earnings this week (NVDA's Q2 FY2027 print confirmed August 26, a beat on EPS and revenue; MRVL's scheduled August 27 print remains unconfirmed in the event record even as market commentary discusses it) — both names cooled on the short window this cycle inside otherwise intact long-horizon trends.

Data as-of the 2026-08-28 close. Source: the pre-captured insider Form-4 report (the desk's own tooling, run this session) cross-referenced against summaries/insider-universe.json for every price/RSI/structure/long-horizon field — this scan uses only the report's dollar-flow columns, never its own price/RSI/change figures, per standing desk doctrine on this tool's cached-column discrepancy. As in prior cycles, the report's own RSI basis differs from the summary's precomputed RSI on RBLX (report reads 36, summary reads 42.4); this scan uses the summary RSI throughout. Prior scan: 2026-08-22-insider-scan.

The insider-buying table stayed completely unchanged for a third straight cycle, both in composition and in dollar terms. TSLA ($348.75, RSI 50.9, was 58.0; 30D +16.9%, was -3.0%) continues with buying frozen at +$219.9M, no fresh filing activity for a sixth-plus straight cycle. CRSP ($57.72, RSI 56.5, was 66.6; 30D +21.16%, was +26.0%) cooled modestly while its buying figure held flat at +$28.1M. ASAN ($10.19, RSI 65.7, was 61.7), INTC ($89.47, RSI 41.5, was 39.6), and TSM ($417.52, RSI 49.6, was 50.4) all show the same pattern — buying figures essentially unchanged (+$8.7M, +$2.4M, +$1.6M) against real price movement underneath. This reads as a continued quiet Form-4 cycle, not a data-fetch gap.

No name in this 59-stock universe closes below RSI 30 for a fourth straight cycle — and the closest reading is a structurally broken name, not a returning one. EOSE ($3.27, RSI 38.5) is the closest to the strict line this cycle, but its longer-horizon numbers confirm this is a broken structure, not a discount: -54.14% on the year, 1-year alpha -74.01%, collapse regime. RBLX ($38.53, RSI 42.4, was 39.9) actually improved off last cycle's reading, though its one-year return worsened to -69.63% (was -66.6%) and it remains -37.3% below its 200-day — still a damaged structure, not a bargain. Insider selling on RBLX moved to -$627.0M, down from -$695.4M. On the golden-signal (RSI<30 plus buying) and selling-into-dip (RSI<30 plus selling) criteria, both again return zero names.

BE's multi-cycle reversal, which cooled sharply last cycle, resumed this cycle. Price rose to $210.77 (RSI 46.3, was 42.6), and the cushion above the 200-day widened back to +11.8% from +8.0% — the 30-day print flipped back to +28.71% from -7.68%. Its one-year return cooled to +284.62% (was +349.36%) as the trailing comparison window rolled forward, and 1-year alpha sits at +264.74%; the regime label (pullback, thesis: intact) is unchanged. Insider selling stayed roughly flat at -$460.8M — still price-driven, not corroborated by fresh insider buying.

MRNA cooled on the short window but kept climbing on the 30-day and one-year windows, still with no known driver. ($137.99, RSI 63.5, was 71.6; 7D -4.89%, RSI cooling off the pullback) — yet 30D is +153.24% (was +149.92%) and one-year is +463.91% (was +453.51%), with vs-SMA200 still enormous at +166.6% (was +197.8%, compressed some but still extreme). This desk checked latest (fetched 2026-08-25T23:40:47Z, ok: true, not stale) and research/stock-events/ for MRNA this session — the pull returns generic quote/aggregator pages, and no event record covers a driver for either the week's pullback or the sustained multi-week climb. This is now the second straight cycle this desk has checked and found nothing; flagged as cause unknown, not glossed over.

ARM's reversal stabilized, undoing last cycle's negative flip. ($239.05, RSI 40, was 39.2; 30D +6.3%, was -14.14%; 7D -1.78%) pulled back slightly on the week but the 30-day print flipped back positive. Its one-year return cooled to +67.7% (was +82.56%) and its 200-day cushion narrowed to +19.9% (was +23.4%) — still a deep pullback inside an intact trend, but the cushion is compressing across two cycles now, worth tracking.

ISRG's divergence between its chart and its thesis flag persisted and worsened this cycle. ($372.60, RSI 45.7, was 47.6; regime still collapse, vs-SMA200 -20.5%, was -19.9%; one-year -21.37%, was -19.38%) — the chart has now spent a second straight cycle below its 200-day with a worsening one-year deficit, while thesisState still reads intact. This divergence is flagged again, not resolved, and is worth a direct fundamentals check.

The semis-adjacent complex broadly cooled on the short window this cycle, coinciding with NVDA's and MRVL's earnings week. NVDA ($217.55, RSI 52.3, unchanged from last cycle's basing regime; change1d -4.57%) reported Q2 FY2027 results after the close on August 26 — confirmed via SEC filing (Form 10-Q and 8-K), revenue $96.221B (+106% YoY), non-GAAP EPS $2.22 versus $2.09 consensus (a beat), with guidance of $108.0B ±2% for Q3 and a preliminary 70% FY2028 revenue-growth outlook. MRVL ($216.62, RSI 47.2, was 55.8; 7D -8.63%) has a scheduled August 27 earnings date that remains unconfirmed in the event record (overdue-unconfirmed) even as news commentary from the same week discusses the print — this scan describes MRVL's decline as earnings-week volatility, not a confirmed beat/miss reaction. AMD (RSI 44.8, was 45.8; 30D +8.38%, was -14.32%, reversed positive; one-year +176.17%, vs-SMA200 +38.7%) and INTC (RSI 41.5, was 39.6; 30D +9.27%, was -12.23%, reversed positive; one-year +258.88%, vs-SMA200 +22.9%) both flipped back positive on 30D while cooling modestly on the year. ASML (RSI 43.4, was 50.5; one-year +122.17%, was +139.84%, vs-SMA200 +15.9%, was +21.9%) cooled on both windows. All four remain deep pullbacks inside intact long-horizon trends.

Heavy insider selling stayed essentially frozen across the top-20 dollar-value names. AMZN (-$9.4B, was -$9.6B), NVDA (-$3.3B, unchanged), LLY (-$3.1B, unchanged), PLTR (-$2.4B, up from -$2.3B), and AVGO (-$1.6B, unchanged) all held roughly their prior-cycle figures. RBLX's selling moved down to -$627.0M from -$695.4M. DDOG's captured figure moved to -$660.6M from -$668.9M. SNOW ticked down to -$1.2B from -$1.3B. AMD's selling moved up slightly to -$425.2M from -$410.2M.

This is a price-and-structure screen cross-referenced with insider Form-4 net dollars — not a recommendation engine. A third straight cycle of zero fresh filings in the buying table is a genuinely quiet read on insider conviction in this universe, not a data gap. A fourth straight cycle with no name below RSI 30 says the tape has stabilized broadly, not that every name is a buy — and this cycle's closest reading (EOSE) is itself a broken structure, not a bargain, which is the distinction this scan exists to draw. Structure labels — intact (golden cross, uptrend/basing), damaged (death cross, downtrend/collapse), extended (large positive vs-SMA200 in an uptrend) — describe the chart only. Per the desk's long-horizon discipline, a cooling or reversing short-window read (BE, ARM, AMD, INTC, ASML) is checked against 1-year change and vs-SMA200 before it gets called a break — all stayed positive this cycle. MRNA's move is reported at full size because it is verified against the summary, and flagged as cause unknown because this desk checked its news receipt and the stock-events ledger and found nothing, for a second straight cycle. NVDA's confirmed Q2 print is cited from its SEC filing and event record, not from news commentary alone; MRVL's is explicitly NOT cited as confirmed, because the event ledger itself still marks it unconfirmed — elapsed time and market chatter don't promote a scheduled event to captured.

(No other name in this universe shows net insider buying above $100K this cycle.)

(52+ names show net insider selling this cycle per the pull; the 20 above are the largest captured.)

None this cycle. EOSE, the closest candidate on the RSI basis (38.5), is not in the top-20 captured selling table.

Buying table frozen for a third cycle — no fresh Form-4 activity across TSLA, CRSP, ASAN, INTC, or TSM; treat the dollar figures as continuing prior conviction, not fresh signal.

Universe-wide clean read extends to a fourth cycle — no name closes below RSI 30 anywhere in this 59-stock universe; both the golden-signal and selling-into-dip criteria return zero, and this cycle's closest name (EOSE) is a broken structure.

Reversal resumed — BE's cushion above the 200-day widened back after cooling sharply last cycle, keeping this read as an intact, if volatile, secular trend.

Reversal stabilized — ARM's 30-day print flipped back positive, though its cushion is compressing across two cycles now.

Structure/thesis divergence, worsening — ISRG's chart deteriorated further while its flag stayed intact; worth a direct check.

Extraordinary, still unexplained — MRNA's 30-day and one-year prints stay the largest in this universe by a wide margin; a second straight cycle with no corpus source for the driver.

Semis-adjacent complex cools inside earnings week — AMD, INTC, ASML all reversed or cooled on the short window while staying deep pullbacks inside intact one-year trends; NVDA's Q2 print is confirmed, MRVL's is not yet.

Heavy selling, intact structure — AMZN, NVDA, LLY, PANW, ABNB, SNOW, NET, DOCN, DDOG, TWLO, AAPL, AMD all show large insider-selling dollars inside intact (golden-cross) technical structure — reads as scale-driven, not a bearish tell on its own.

Heavy selling, damaged structure — verification-worthy — PLTR, NFLX, COIN, SOFI, ESTC, RBLX.

• Tape data (price/RSI/SMA/returns/1-year change/1-year alpha/vs 200-day): full-scan pre-computed summaries as of the 2026-08-28 close — insider-universe.
• Insider Form-4 net dollar flows: pre-captured insider-scan:full report (run this session).
• NVDA Q2 FY2027 earnings: confirmed via 2026-08-26-nvda-earnings (SEC Form 10-Q/8-K, beat vs. consensus).
• MRVL earnings status: 2026-08-27-mrvl-earnings (scheduled date passed, print unconfirmed).
• MRNA news/event check: latest (fetched 2026-08-25, ok, not stale); research/stock-events/ searched for MRNA — no driver found.